Article
Gastroenterology & Hepatology
Laura Maas, Ruiyi Gao, Vivy Cusumano, Ellen Spartz, Reezwana Chowdhury, Mahesh Krishna, Mark Lazarev, Joanna Melia, Florin Selaru, Sowmya Sharma, Berkeley Limketkai, Alyssa Parian
Summary: This study compared the efficacy of infliximab (IFX) and adalimumab (ADA) in healing CD-PAF. The results showed that the IFX group had better clinical response at 6 months and higher biologic persistence. In addition, the study supported the use of concomitant immunomodulator therapy for CD-PAF healing and remission.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Infectious Diseases
Matthew P. Velez, Matthew W. McCarthy
Summary: As the SARS-CoV-2 pandemic continues, there is an urgent need for better therapies to address the waning vaccine efficacy and emergence of highly contagious subvariants. A randomized placebo-controlled clinical trial has shown that the use of infliximab, a chimeric monoclonal antibody, can significantly reduce mortality and improve clinical status in hospitalized patients with COVID-19.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2023)
Article
Pharmacology & Pharmacy
Beatriz Orts, Ana Gutierrez, Lucia Madero, Laura Sempere, Ruben Frances, Pedro Zapater
Summary: There are differences in the immunological profile and clinical evolution of patients with Crohn's disease according to the anti-TNF dose and serum trough levels.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Gastroenterology & Hepatology
Walter Reinisch, Krisztina Gecse, Jonas Halfvarson, Peter M. Irving, Jorgen Jahnsen, Laurent Peyrin-Biroulet, Gerhard Rogler, Stefan Schreiber, Silvio Danese
Summary: The introduction of TNF inhibitors has revolutionized the treatment of Crohn's disease, but there are still differences in the actual application of evidence-based guidelines, leading to treatment disparities between countries. The availability of biosimilars can help reduce health inequalities caused by variations in drug availability.
INFLAMMATORY BOWEL DISEASES
(2021)
Review
Gastroenterology & Hepatology
Walter Reinisch, Krisztina Gecse, Jonas Halfvarson, Peter M. Irving, Jorgen Jahnsen, Laurent Peyrin-Biroulet, Gerhard Rogler, Stefan Schreiber, Silvio Danese
Summary: This review by European IBD experts discusses the practical use of anti-TNF therapy, including biosimilars, for adult patients with Crohn's disease. Despite the significant impact of TNF inhibitors in changing treatment goals, disparities still exist in translating evidence-based guidelines into actual treatment algorithms. The introduction of biosimilars aims to minimize health inequalities in drug availability and provides clinical guidance for different scenarios encountered during treatment with infliximab and adalimumab biosimilars in patients with moderate to severe CD.
INFLAMMATORY BOWEL DISEASES
(2021)
Article
Gastroenterology & Hepatology
Bonita Gu, Kavya Venkatesh, Astrid-Jane Williams, Watson Ng, Crispin Corte, Ali Gholamrezaei, Simon Ghaly, Wei Xuan, Sudarshan Paramsothy, Susan Connor
Summary: Maintenance infliximab and adalimumab trough levels are associated with perianal fistula healing in CD. Patients who achieved fistula healing had significantly higher drug trough levels compared to those who did not.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Yan-Fei Fang, Xiang-Han Cao, Ling-Ya Yao, Qian Cao
Summary: This study reports three cases of pulmonary cryptococcosis in patients with Crohn's disease following immunomodulatory treatment. The patients presented with pulmonary nodules in unilateral or bilateral lobes on chest CT scans. Diagnoses were confirmed through pathological examination and metagenomic sequencing. Treatment with fluconazole 400 mg once daily resulted in symptom resolution. Literature searches were conducted to summarize patient characteristics.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Julien Kirchgesner, Rishi J. Desai, Maria C. Schneeweiss, Laurent Beaugerie, Sebastian Schneeweiss, Seoyoung C. Kim
Summary: Combination therapy with vedolizumab and thiopurines is associated with a lower risk of treatment failure compared to vedolizumab monotherapy in patients with CD, but the effect is less pronounced in UC.
Article
Gastroenterology & Hepatology
Eun Sil Kim, Sujin Choi, So Yoon Choi, Ji Hyung Park, Byung-Ho Choe, Soo-Youn Lee, Mi Jin Kim, Yon Ho Choe, Ben Kang
Summary: NUDT15 intermediate metabolisers are associated with lower loss of response in pediatric patients with CD treated with IFX and AZA combination therapy.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Medicine, General & Internal
Maryia Zhdanava, Zhijie Ding, Ameur M. Manceur, Erik Muser, Patrick Lefebvre, Christopher Holiday, Marie-Helene Lafeuille, Dominic Pilon
Summary: The objective of this study was to compare persistence and describe dose titration among bio-naive patients with Crohn's disease (CD) initiated on ustekinumab or adalimumab. The results showed that patients initiated on ustekinumab had higher persistence on the index biologic compared to those initiated on adalimumab, and they also had lower dose escalation rates and higher de-escalation rates.
CURRENT MEDICAL RESEARCH AND OPINION
(2023)
Review
Gastroenterology & Hepatology
Eun Sil Kim, Ben Kang
Summary: The selection of biologic agents for pediatric Crohn's disease should be done carefully, as currently only infliximab and adalimumab are approved for use in children. Lack of comparison trials in pediatric patients necessitates the extrapolation of adult data. From a pharmacokinetic perspective, infliximab may be more advantageous in high inflammatory burden, while adalimumab may be better in sustaining remission during maintenance phase. Factors such as clinical indications, disease behavior, efficacy, safety, immunogenicity, patient preference, and compliance should be considered when choosing anti-TNF therapy.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Immunology
Shin Ju Oh, Young Nam Kwon, Chang Kyun Lee, Jin San Lee
Summary: This is the first report of infliximab-associated anti-NMDAR encephalitis in Crohn's disease, highlighting the need for clinicians to recognize the possibility of a paradoxical autoimmune response occurring with novel biological therapies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
C. Erdogan, M. B. Durak, A. Alkan, V. Kilic, F. Kivrakoglu, K. Kosar, I. Yuksel
Summary: This study evaluated the long-term clinical effectiveness and safety of infliximab (IFX) and adalimumab (ADA) in Crohn's disease patients who had not previously received a biologic treatment. The results showed no significant differences in the long-term effectiveness and safety of IFX and ADA in biologic-naive patients with CD.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2023)
Letter
Gastroenterology & Hepatology
Benedicte Caron, Mathurin Fumery, Patrick Netter, Laurent Peyrin-Biroulet
Summary: This article is linked to the papers by Hanzel et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Medicine, General & Internal
Laura Janssen, Marielle Romberg-Camps, Ad van Bodegraven, Jeoffrey Haans, Michel Aquarius, Paul Boekema, Tamara Munnecom, Lloyd Brandts, Manuela Joore, Adrian Masclee, D. Jonkers, M. Pierik
Summary: Crohn's disease is a chronic inflammatory bowel disease with heterogeneous clinical presentation and treatment response. This study aims to compare episodic treatment with adalimumab monotherapy to a step-up approach starting with corticosteroids in newly diagnosed or flaring CD patients. The primary outcome is the number of quarterly corticosteroid-free clinical and biochemical remission at week 96.
Letter
Rheumatology
Samuel Deshayes, Jacques Callebert, Jean-Marie Launay, Achille Aouba, Harry Sokol, Sophie Georgin-Lavialle
MODERN RHEUMATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Lucile Dheyriat, Daniel Ward, Laurent Beaugerie, Tine Jess, Julien Kirchgesner
Summary: Patients with inflammatory bowel disease (IBD) are at increased risk of acute arterial events. The use of anti-tumor necrosis factor (anti-TNF) agents has a protective effect against the first occurrence of acute arterial events. In this study, the effect of anti-TNF and thiopurines on the risk of recurrent acute arterial events in IBD patients with a previous history of such events was assessed.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Lucas Guillo, Benoit Flachaire, Jerome Avouac, Catherine Dong, Maria Nachury, Guillaume Bouguen, Anthony Buisson, Ludovic Caillo, Mathurin Fumery, Cyrielle Gilletta, Xavier Hebuterne, Pierre Lafforgue, David Laharie, Emmanuel Mahe, Hubert Marotte, Stephane Nancey, Sebastien Ottaviani, Jean-Hugues Salmon, Guillaume Savoye, Melanie Serrero, Mathieu Uzzan, Manuelle Viguier, Christophe Richez, Laurent Peyrin-Biroulet, Philipe Seksik, Thao Pham
Summary: In a French multicenter cohort study, the effectiveness and safety of combination therapies (COMBIO) were assessed in patients with refractory/overlapping immune-mediated inflammatory diseases (IMIDs).
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Laurent Peyrin-Biroulet, Jean-Francois Rahier, Julien Kirchgesner, Vered Abitbol, Sebastian Shaji, Alessandro Armuzzi, Konstantinos Karmiris, Javier P. Gisbert, Peter Bossuyt, Ulf Helwig, Johan Burisch, Henit Yanai, Glen A. Doherty, Fernando Magro, Tamas Molnar, Mark Lowenberg, Jonas Halfvarson, Edyta Zagorowicz, Helene Rousseau, Cedric Baumann, Filip Baert, Laurent Beaugerie
Summary: The I-CARE study aims to evaluate the benefit-risk ratio of current therapies in IBD patients. It collected data from 10,206 patients and observed the treatment risks of anti-tumor necrosis factor and other biologic therapies, particularly the risks of cancer/lymphoma and serious infections. The results showed that different treatment regimens had varying effects on patients, and further research is needed to assess specific risks.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Camille Danne, Chloe Michaudel, Jurate Skerniskyte, Julien Planchais, Aurelie Magniez, Allison Agus, Marie-Laure Michel, Bruno Lamas, Gregory Da Costa, Madeleine Spatz, Cyriane Oeuvray, Chloe Galbert, Maxime Poirier, Yazhou Wang, Alexia Lapiere, Nathalie Rolhion, Tatiana Ledent, Cedric Pionneau, Solenne Chardonnet, Floriant Bellvert, Edern Cahoreau, Amandine Rocher, Rafael Rose Arguello, Carole Peyssonnaux, Sabine Louis, Mathias L. Richard, Philippe Langella, Jamel El-Benna, Benoit Marteyn, Harry Sokol
Summary: Inflammatory bowel disease (IBD) is caused by a combination of genetic predisposition, gut microbiota dysbiosis, and environmental factors. Caspase recruitment domain 9 (Card9) is an IBD susceptibility gene that has been shown to protect against intestinal inflammation and fungal infection. However, the specific cell types and mechanisms involved in the CARD9 protective role against inflammation are still unknown.
Article
Gastroenterology & Hepatology
Chloe Michaudel, Camille Danne, Allison Agus, Aurelie Magniez, Anne Aucouturier, Madeleine Spatz, Antoine Lefevre, Julien Kirchgesner, Nathalie Rolhion, Yazhou Wang, Aonghus Lavelle, Chloe Galbert, Gregory Da Costa, Maxime Poirier, Alexia Lapiere, Julien Planchais, Petr Nadvornik, Peter Illes, Cyriane Oeuvray, Laura Creusot, Marie-Laure Michel, Nicolas Benech, Anne Bourrier, Isabelle Nion-Larmurier, Cecilia Landman, Mathias L. Richard, Patrick Emond, Philippe Seksik, Laurent Beaugerie, Rafael Rose Arguello, David Moulin, Sridhar Mani, Zdenek Dvorak, Luis G. Bermudez-Humaran, Philippe Langella, Harry Sokol
Summary: This study identified a new mechanism linking tryptophan metabolism to intestinal inflammation and inflammatory bowel diseases (IBDs). Bringing back xanthurenic acid (XANA) and kynurenic acid (KYNA) has protective effects involving Aryl hydrocarbon Receptor (AhR) activation and the rewiring of cellular energy metabolism in intestinal epithelial cells and CD4(+) T cells. Manipulating the endogenous metabolic pathway with aminoadipate aminotransferase (AADAT) may provide new therapeutic strategies for correcting tryptophan metabolism alterations in IBD.
Article
Multidisciplinary Sciences
Katherine M. Kennedy, Marcus C. de Goffau, Maria Elisa Perez-Munoz, Marie-Claire Arrieta, Fredrik Backhed, Peer Bork, Thorsten Braun, Frederic D. Bushman, Joel Dore, Willem M. de Vos, Ashlee M. Earl, Jonathan A. Eisen, Michal A. Elovitz, Stephanie C. Ganal-Vonarburg, Michael G. Ganzle, Wendy S. Garrett, Lindsay J. Hall, Mathias W. Hornef, Curtis Huttenhower, Liza Konnikova, Sarah Lebeer, Andrew J. Macpherson, Ruth C. Massey, Alice Carolyn McHardy, Omry Koren, Trevor D. Lawley, Ruth E. Ley, Liam O'Mahony, Paul W. O'Toole, Eric G. Pamer, Julian Parkhill, Jeroen Raes, Thomas Rattei, Anne Salonen, Eran Segal, Nicola Segata, Fergus Shanahan, Deborah M. Sloboda, Gordon C. S. Smith, Harry Sokol, Tim D. Spector, Michael G. Surette, Gerald W. Tannock, Alan W. Walker, Moran Yassour, Jens Walter
Summary: The colonization of microbial communities in the human fetus and the prenatal intrauterine environment is still controversial. Recent studies analyzing microbial populations in human fetuses indicate that the detected signals might be due to contamination during sample collection or DNA sequencing processes. The presence of live and replicating microbial populations in healthy fetal tissues contradicts fundamental concepts in immunology and clinical microbiology. This has significant implications for our understanding of human immune development and highlights the challenges in studying microbial communities in low-biomass environments.
Article
Substance Abuse
Tetsuya Kouno, Suling Zeng, Yanhan Wang, Yi Duan, Sonja Lang, Bei Gao, Phillipp Hartmann, Noemi Cabre, Cristina Llorente, Chloe Galbert, Patrick Emond, Harry Sokol, Michael James, Chun Cheih Chao, Jian-Rong Gao, Mylene Perreault, David L. Hava, Bernd Schnabl
Summary: This study demonstrates that engineering gut bacteria to produce tryptophan metabolites can alleviate liver disease caused by alcohol through Ahr activation in intestinal immune cells.
ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH
(2023)
Article
Medicine, General & Internal
Aurore Douge, Aurelie Ravinet, Alexandrine Corriger, Aurelie Cabrespine, Mathieu Wasiak, Bruno Pereira, Harry Sokol, Stephanie Nguyen, Jacques-Olivier Bay
Summary: This study aims to evaluate the effect of fecal microbiota transplantation (FMT) on toxicity in patients undergoing myeloablative allo-HSCT. The study will include 60 male and female patients, randomly assigned to two groups, one receiving FMT and one as a control group. The primary endpoint is the GvHD-free relapse-free survival rate at 1 year after allo-HSCT. The results of this study will be disseminated through peer-reviewed publications and conferences.
Article
Cell Biology
Paolo Manghi, Aitor Blanco-Miguez, Serena Manara, Amir NabiNejad, Fabio Cumbo, Francesco Beghini, Federica Armanini, Davide Golzato, Kun D. Huang, Andrew M. Thomas, Gianmarco Piccinno, Michal Puncochar, Moreno Zolfo, Till R. Lesker, Marius Bredon, Julien Planchais, Jeremy Glodt, Mireia Valles-Colomer, Omry Koren, Edoardo Pasolli, Francesco Asnicar, Till Strowig, Harry Sokol, Nicola Segata
Summary: In this study, the researchers used MetaPhlAn 4, a metagenomic profiling method, to improve the analysis of the mouse gut microbiome. By combining multiple datasets and additional samples, they were able to identify several diet-related microbial biomarkers, including previously unknown ones.
Article
Genetics & Heredity
Daniela Matuozzo, Estelle Talouarn, Astrid Marchal, Peng Zhang, Jeremy Manry, Yoann Seeleuthner, Yu Zhang, Alexandre Bolze, Matthieu Chaldebas, Baptiste Milisavljevic, Adrian Gervais, Paul Bastard, Takaki Asano, Lucy Bizien, Federica Barzaghi, Hassan Abolhassani, Ahmad Abou Tayoun, Alessandro Aiuti, Ilad Alavi Darazam, Luis M. Allende, Rebeca Alonso-Arias, Andres Augusto Arias, Gokhan Aytekin, Peter Bergman, Simone Bondesan, Yenan T. Bryceson, Ingrid G. Bustos, Oscar Cabrera-Marante, Sheila Carcel, Paola Carrera, Giorgio Casari, Khalil Chaibi, Roger Colobran, Antonio Condino-Neto, Laura E. Covill, Ottavia M. Delmonte, Loubna El Zein, Carlos Flores, Peter K. Gregersen, Marta Gut, Filomeen Haerynck, Rabih Halwani, Selda Hancerli, Lennart Hammarstroem, Nevin Hatipoglu, Adem Karbuz, Sevgi Keles, Christele Kyheng, Rafael Leon-Lopez, Jose Luis Franco, Davood Mansouri, Javier Martinez-Picado, Ozge Metin Akcan, Isabelle Migeotte, Pierre-Emmanuel Morange, Guillaume Morelle, Andrea Martin-Nalda, Giuseppe Novelli, Antonio Novelli, Tayfun Ozcelik, Figen Palabiyik, Qiang Pan-Hammarstroem, Rebeca Perez de Diego, Laura Planas-Serra, Daniel E. Pleguezuelo, Carolina Prando, Aurora Pujol, Luis Felipe Reyes, Jacques G. Riviere, Carlos Rodriguez-Gallego, Julian Rojas, Patrizia Rovere-Querini, Agatha Schlueter, Mohammad Shahrooei, Ali Sobh, Pere Soler-Palacin, Yacine Tandjaoui-Lambiotte, Imran Tipu, Cristina Tresoldi, Jesus Troya, Diederik van de Beek, Mayana Zatz, Pawel Zawadzki, Saleh Zaid Al-Muhsen, Mohammed Faraj Alosaimi, Fahad M. Alsohime, Hagit Baris-Feldman, Manish J. Butte, Stefan N. Constantinescu, Megan A. Cooper, Clifton L. Dalgard, Jacques Fellay, James R. Heath, Yu-Lung Lau, Richard P. Lifton, Tom Maniatis, Trine H. Mogensen, Horst von Bernuth, Alban Lermine, Michel Vidaud, Anne Boland, Jean-Francois Deleuze, Robert Nussbaum, Amanda Kahn-Kirby, France Mentre, Sarah Tubiana, Guy Gorochov, Florence Tubach, Pierre Hausfater, C. O. V. I. D. Human Genetic Effort, Isabelle Meyts, Shen-Ying Zhang, Anne Puel, Luigi D. Notarangelo, Stephanie Boisson-Dupuis, Helen C. Su, Bertrand Boisson, Emmanuelle Jouanguy, Jean-Laurent Casanova, Qian Zhang, Laurent Abel, Aurelie Cobat
Summary: Through a genome-wide rare variant burden association analysis, it was found that there is an association between at-risk variants in the TLR7 gene and rare loss-of-function variants in TLR3-dependent type I interferon immunity genes. These findings suggest that rare variants in TLR3- and TLR7-dependent type I interferon immunity genes may underlie life-threatening COVID-19 in patients under 60 years old.
Article
Geriatrics & Gerontology
Adeline Dolly, Sarah A. Potgens, Morgane M. Thibaut, Audrey M. Neyrinck, Gabriela S. de Castro, Chloe Galbert, Camille Lefevre, Elisabeth Wyart, Silvio P. Gomes, Daniela C. Goncalves, Nicolas Lanthier, Pamela Baldin, Joshua R. Huot, Andrea Bonetto, Marilia Seelaender, Nathalie M. Delzenne, Harry Sokol, Laure B. Bindels
Summary: This study explores the potential role of the aryl hydrocarbon receptor (AHR) in cancer cachexia and finds that impaired AHR signaling contributes to hepatic inflammatory and metabolic disorders, exacerbating cachectic features. These findings provide innovative therapeutic strategies for cancer cachexia.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2023)
Article
Immunology
Leslie Landemaine, Gregory Da Costa, Elsa Fissier, Carine Francis, Stanislas Morand, Jonathan Verbeke, Marie-Laure Michel, Romain Briandet, Harry Sokol, Audrey Gueniche, Dominique Bernard, Jean-Marc Chatel, Luc Aguilar, Philippe Langella, Cecile Clavaud, Mathias L. Richard
Summary: This study demonstrates that Staphylococcus epidermidis strains originating from healthy skin and atopic skin have different effects. Strains from atopic skin alter the structure of a 3D reconstructed skin model, while strains from healthy skin do not. The metabolites produced by strains from healthy skin can activate the aryl hydrocarbon receptor pathway, while strains from atopic skin cannot.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Gastroenterology & Hepatology
Yoram Bouhnik, Bruno Fautrel, Laurent Beaugerie, Anne-Laure Pelletier, Christine Martinez-Vinson, Ulrich Freudensprung, Amira Brigui, Janet Addison, PERFUSE investigators
Summary: This study evaluated the persistence, effectiveness, and safety of SB2 over 12 months in IBD patients. The results showed that more than 75% of IFX-naive patients and more than 90% of patients previously treated with IFX continued with SB2 treatment at 12 months, with no loss of disease control or safety concerns.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)